Identification

Name
Felodipine
Accession Number
DB01023  (APRD00374)
Type
Small Molecule
Groups
Approved, Investigational
Description

Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte contraction and vasoconstriction. Felodipine is the most potent CCB in use and is unique in that it exhibits fluorescent activity. In addition to binding to L-type calcium channels, felodipine binds to a number of calcium-binding proteins, exhibits competitive antagonism of the mineralcorticoid receptor, inhibits the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase, and blocks calcium influx through voltage-gated T-type calcium channels. Felodipine is used to treat mild to moderate essential hypertension.

Structure
Thumb
Synonyms
  • (+-)-Ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate
  • 3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate
  • 4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester
  • Felodipina
  • Felodipine
  • Felodipinum
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Felodipineextended-release TabletsTablet, extended release2.5 mg/1OralRanbaxy Inc.2008-09-10Not applicableUs
Felodipineextended-release TabletsTablet, extended release5 mg/1OralRanbaxy Inc.2008-09-10Not applicableUs
Felodipineextended-release TabletsTablet, extended release10 mg/1OralRanbaxy Inc.2008-09-10Not applicableUs
PlendilTablet, extended release2.5 mg/1OralAstra Zeneca Lp1994-10-042016-11-04Us
PlendilTablet, extended release10 mg/1Oralbryant ranch prepack1991-09-16Not applicableUs
PlendilTablet, extended release5 mg/1OralAstra Zeneca Lp1991-09-162016-11-04Us
PlendilTablet, extended release10 mg/1OralAstra Zeneca Lp1991-09-162016-11-04Us
Plendil 10 mgTablet, extended release10 mgOralAstra Zeneca1992-12-31Not applicableCanada
Plendil 2.5 mgTablet, extended release2.5 mgOralAstra Zeneca1994-12-31Not applicableCanada
Plendil 5 mgTablet, extended release5 mgOralAstra Zeneca1992-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-felodipineTablet, extended release5 mgOralApotex Corporation2016-04-22Not applicableCanada
Apo-felodipineTablet, extended release10 mgOralApotex Corporation2016-04-22Not applicableCanada
Apo-felodipineTablet, extended release2.5 mgOralApotex Corporation2016-04-22Not applicableCanada
FelodipineTablet, film coated, extended release10 mg/1OralWockhardt2010-12-05Not applicableUs
FelodipineTablet, extended release2.5 mg/1OralQualitest2009-03-31Not applicableUs
FelodipineTablet, extended release5 mg/1OralAmerincan Health Packaging2014-12-15Not applicableUs
FelodipineTablet, film coated, extended release2.5 mg/1OralJubilant Cadista Pharmaceuticals Inc.2016-08-19Not applicableUs
FelodipineTablet, film coated, extended release10 mg/1OralPhysicians Total Care, Inc.2005-01-21Not applicableUs53489 0370 01 nlmimage10 35339aec
FelodipineTablet, extended release10 mg/1OralHeritage2013-11-08Not applicableUs
FelodipineTablet, film coated, extended release10 mg/1OralWockhardt2010-12-05Not applicableUs
International/Other Brands
Felodur ER / Felogard / Penedil / Plendil Depottab (AstraZeneca) / Plendil ER (AstraZeneca) / Plendil Retard (AstraZeneca) / Splendil
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Altace Plus Felodipine 2.5mg + 2.5mgFelodipine (2.5 mg) + Ramipril (2.5 mg)TabletOralSanofi Aventis2006-06-272012-10-10Canada
Altace Plus Felodipine 5mg + 5mgFelodipine (5 mg) + Ramipril (5 mg)TabletOralSanofi Aventis2006-06-272012-10-15Canada
Categories
UNII
OL961R6O2C
CAS number
72509-76-3
Weight
Average: 384.254
Monoisotopic: 383.069113515
Chemical Formula
C18H19Cl2NO4
InChI Key
RZTAMFZIAATZDJ-UHFFFAOYSA-N
InChI
InChI=1S/C18H19Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8,15,21H,5H2,1-4H3
IUPAC Name
3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC

Pharmacology

Indication

For the treatment of mild to moderate essential hypertension.

Structured Indications
Pharmacodynamics

Felodipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. There are at least five different types of calcium channels in Homo sapiens: L-, N-, P/Q-, R- and T-type. It was widely accepted that CCBs target L-type calcium channels, the major channel in muscle cells that mediates contraction; however, some studies have shown that felodipine also binds to and inhibits T-type calcium channels. T-type calcium channels are most commonly found on neurons, cells with pacemaker activity and on osteocytes. The pharmacologic significance of T-type calcium channel blockade is unknown. Felodipine also binds to calmodulin and inhibits calmodulin-dependent calcium release from the sarcoplasmic reticulum. The effect of this interaction appears to be minor. Another study demonstrated that felodipine attenuates the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase (CaMPDE) by binding to the PDE-1B1 and PDE-1A2 enzyme subunits. CaMPDE is one of the key enzymes involved in cyclic nucleotides and calcium second messenger systems. Felodipine also acts as an antagonist to the mineralcorticoid receptor by competing with aldosterone for binding and blocking aldosterone-induced coactivator recruitment of the mineralcorticoid receptor. Felodipine is able to bind to skeletal and cardiac muscle isoforms of troponin C, one of the key regulatory proteins in muscle contraction. Though felodipine exhibits binding to many endogenous molecules, its vasodilatory effects are still thought to be brought about primarily through inhibition of voltage-gated L-type calcium channels. Similar to other DHP CCBs, felodipine binds directly to inactive calcium channels stabilizing their inactive conformation. Since arterial smooth muscle depolarizations are longer in duration than cardiac muscle depolarizations, inactive channels are more prevalent in smooth muscle cells. Alternative splicing of the alpha-1 subunit of the channel gives felodipine additional arterial selectivity. At therapeutic sub-toxic concentrations, felodipine has little effect on cardiac myocytes and conduction cells.

Mechanism of action

Felodipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through voltage-gated L-type calcium channels. It reversibly competes against nitrendipine and other DHP CCBs for DHP binding sites in vascular smooth muscle and cultured rabbit atrial cells. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium decreases the contractile activity of arterial smooth muscle cells and results in vasodilation. The vasodilatory effects of felodipine result in an overall decrease in blood pressure. Felodipine may be used to treat mild to moderate essential hypertension.

TargetActionsOrganism
AVoltage-dependent L-type calcium channel subunit alpha-1C
inhibitor
Human
AVoltage-dependent calcium channel subunit alpha-2/delta-1
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit beta-2
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1D
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1S
inhibitor
Human
UVoltage-dependent T-type calcium channel subunit alpha-1H
inhibitor
Human
UVoltage-dependent calcium channel subunit alpha-2/delta-2
inhibitor
Human
UCalmodulin
other
Human
UCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B
inhibitor
Human
UCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A
inhibitor
Human
UMineralocorticoid receptor
antagonist
Human
UTroponin C, skeletal muscle
other
Human
UTroponin C, slow skeletal and cardiac muscles
other
Human
Absorption

Is completely absorbed from the gastrointestinal tract; however, extensive first-pass metabolism through the portal circulation results in a low systemic availability of 15%. Bioavailability is unaffected by food.

Volume of distribution
  • 10 L/kg
Protein binding

99%, primarily to the albumin fraction.

Metabolism

Hepatic metabolism primarily via cytochrome P450 3A4. Six metabolites with no appreciable vasodilatory effects have been identified.

Route of elimination

Although higher concentrations of the metabolites are present in the plasma due to decreased urinary excretion, these are inactive. Animal studies have demonstrated that felodipine crosses the blood-brain barrier and the placenta.

Half life

17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.

Clearance
  • 0.8 L/min [Young healthy subjects]
Toxicity

Symptoms of overdose include excessive peripheral vasodilation with marked hypotension and possibly bradycardia. Oral rat LD50 is 1050 mg/kg.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Felodipine Metabolism PathwayDrug metabolism
Felodipine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Felodipine.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Felodipine.Vet Approved
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Felodipine.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Felodipine is combined with Acebutolol.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Felodipine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Felodipine.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Felodipine.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Felodipine.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Felodipine.Experimental
AlfuzosinAlfuzosin may increase the hypotensive activities of Felodipine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Felodipine is combined with Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Felodipine.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Felodipine.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Felodipine.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Felodipine.Approved, Investigational
AmifostineFelodipine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Felodipine.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Felodipine.Approved, Withdrawn
AmiodaroneThe metabolism of Felodipine can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Felodipine.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Felodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Felodipine.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Felodipine.Approved
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Felodipine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Felodipine.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Felodipine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Felodipine is combined with Amyl Nitrite.Approved
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Felodipine.Approved, Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Felodipine.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Felodipine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Felodipine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Felodipine.Approved
AprepitantThe serum concentration of Felodipine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Felodipine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Felodipine.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Felodipine.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Felodipine.Approved
AtazanavirThe metabolism of Felodipine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Felodipine.Approved
AtomoxetineThe metabolism of Felodipine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Felodipine is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Felodipine is combined with Atosiban.Approved
Atracurium besylateFelodipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Felodipine.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Felodipine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Felodipine is combined with Azilsartan medoxomil.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Felodipine.Experimental
BarbexacloneBarbexaclone may increase the hypotensive activities of Felodipine.Experimental
BarbitalBarbital may increase the hypotensive activities of Felodipine.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Felodipine.Approved
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Felodipine.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Felodipine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Felodipine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Felodipine.Withdrawn
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Felodipine.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Felodipine.Approved
BepridilFelodipine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BeraprostThe metabolism of Beraprost can be decreased when combined with Felodipine.Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Felodipine.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Felodipine.Approved
BethanidineBethanidine may increase the hypotensive activities of Felodipine.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Felodipine.Experimental
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Felodipine.Approved
BimatoprostBimatoprost may increase the hypotensive activities of Felodipine.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Felodipine.Approved
BoceprevirThe metabolism of Felodipine can be decreased when combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Felodipine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Felodipine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Felodipine.Approved
BQ-123Felodipine may increase the hypotensive activities of BQ-123.Investigational
Brefeldin AThe risk or severity of adverse effects can be increased when 1,6,7,8,9,11A,12,13,14,14A-DECAHYDRO-1,13-DIHYDROXY-6-METHYL-4H-CYCLOPENT[F]OXACYCLOTRIDECIN-4-ONE is combined with Felodipine.Experimental
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Felodipine.Approved
BretyliumThe risk or severity of adverse effects can be increased when Felodipine is combined with Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Felodipine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Felodipine.Experimental
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Felodipine.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Felodipine.Approved
BucindololBucindolol may increase the hypotensive activities of Felodipine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Felodipine.Approved
BunazosinBunazosin may increase the hypotensive activities of Felodipine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Felodipine.Approved, Investigational
BupranololFelodipine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Felodipine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Felodipine.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Felodipine.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Felodipine.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Felodipine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Felodipine.Approved
CadralazineCadralazine may increase the hypotensive activities of Felodipine.Experimental
CafedrineFelodipine may increase the hypotensive activities of Cafedrine.Investigational
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Felodipine.Approved
CalciumThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium.Nutraceutical
Calcium AcetateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Acetate.Approved
Calcium CarbonateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Carbonate.Approved
Calcium CitrateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium lactate.Approved, Experimental, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium laevulateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium laevulate.Experimental
Calcium pangamateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Phosphate.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Felodipine.Experimental
CanagliflozinThe risk or severity of adverse effects can be increased when Felodipine is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan is combined with Felodipine.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Felodipine.Withdrawn
CandoxatrilCandoxatril may increase the hypotensive activities of Felodipine.Experimental
Capric acidThe risk or severity of adverse effects can be increased when Capric acid is combined with Felodipine.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Felodipine is combined with Captopril.Approved
CarbamazepineThe metabolism of Felodipine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Felodipine.Approved
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Felodipine.Approved
CarbomycinThe metabolism of Felodipine can be decreased when combined with Carbomycin.Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Felodipine.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Felodipine.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Felodipine.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Felodipine is combined with Carvedilol.Approved, Investigational
CaseinThe therapeutic efficacy of Felodipine can be decreased when used in combination with Casein.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Felodipine.Approved
CeliprololFelodipine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Felodipine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Felodipine.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Felodipine.Approved
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Felodipine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Felodipine.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Felodipine.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Felodipine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Felodipine.Approved
CicletanineFelodipine may increase the hypotensive activities of Cicletanine.Investigational
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Felodipine.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Felodipine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Felodipine.Approved
CimetidineThe serum concentration of Felodipine can be increased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Felodipine.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Felodipine.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Felodipine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Felodipine.Approved
ClarithromycinThe metabolism of Felodipine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Felodipine can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Clevidipine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Felodipine.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Felodipine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Felodipine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Felodipine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Felodipine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Felodipine.Approved, Nutraceutical
CloranololFelodipine may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Felodipine.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Felodipine.Approved
CobicistatThe metabolism of Felodipine can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Felodipine.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Felodipine.Approved
ConivaptanThe serum concentration of Felodipine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Felodipine.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Felodipine.Approved
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Felodipine.Investigational
CrizotinibThe metabolism of Felodipine can be decreased when combined with Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Felodipine.Approved
CyclopenthiazideFelodipine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Felodipine.Approved, Investigational
CyclosporineThe metabolism of Felodipine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Felodipine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Felodipine.Approved
DabrafenibThe serum concentration of Felodipine can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Felodipine.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Felodipine is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Felodipine.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Felodipine.Approved, Investigational
DarunavirThe metabolism of Felodipine can be decreased when combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Felodipine.Approved
DasatinibThe serum concentration of Felodipine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Felodipine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Felodipine.Approved
DeferasiroxThe serum concentration of Felodipine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilFelodipine may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe metabolism of Felodipine can be decreased when combined with Delavirdine.Approved
DeserpidineFelodipine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Felodipine.Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Felodipine.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Felodipine.Approved, Vet Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Felodipine.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Felodipine.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Felodipine.Approved
DichloropheneThe risk or severity of adverse effects can be increased when Dichlorophene is combined with Felodipine.Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Felodipine.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Felodipine is combined with Diclofenamide.Approved
diethylnorspermineFelodipine may increase the hypotensive activities of diethylnorspermine.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Felodipine.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Felodipine.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Felodipine.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Felodipine.Investigational
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Felodipine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Felodipine.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Felodipine.Experimental
DihydroergotamineThe metabolism of Felodipine can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Felodipine.Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Felodipine.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Felodipine is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Felodipine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Felodipine.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Felodipine.Approved, Investigational, Vet Approved
DorzolamideDorzolamide may increase the hypotensive activities of Felodipine.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Felodipine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Felodipine.Approved, Investigational
DoxycyclineThe metabolism of Felodipine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Felodipine can be decreased when combined with Dronedarone.Approved
DuloxetineFelodipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Felodipine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Felodipine.Approved
EfavirenzThe serum concentration of Felodipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Felodipine.Approved
EfonidipineFelodipine may increase the hypotensive activities of Efonidipine.Approved
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Felodipine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Felodipine.Approved, Investigational
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Felodipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Felodipine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Felodipine.Approved, Vet Approved
EnalaprilatFelodipine may increase the hypotensive activities of Enalaprilat.Approved
EnasidenibThe serum concentration of Enasidenib can be increased when it is combined with Felodipine.Approved
EndralazineEndralazine may increase the hypotensive activities of Felodipine.Experimental
EnzalutamideThe serum concentration of Felodipine can be decreased when it is combined with Enzalutamide.Approved
EpanololFelodipine may increase the hypotensive activities of Epanolol.Experimental
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Felodipine.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Felodipine.Approved
EpoprostenolFelodipine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Felodipine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Felodipine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Felodipine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Felodipine.Approved, Investigational
ErythromycinThe metabolism of Felodipine can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Felodipine.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Felodipine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Felodipine.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Felodipine.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Felodipine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Felodipine.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Felodipine.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Felodipine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Felodipine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Felodipine.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Felodipine.Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Felodipine.Experimental
Ferulic acidFelodipine may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Felodipine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Felodipine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Felodipine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Felodipine.Approved
FluconazoleThe serum concentration of Felodipine can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Felodipine.Approved
FluorouracilThe metabolism of Fluorouracil can be decreased when combined with Felodipine.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Felodipine.Approved
FlutrimazoleThe risk or severity of adverse effects can be increased when Flutrimazole is combined with Felodipine.Experimental
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Felodipine.Approved
FluvoxamineThe metabolism of Felodipine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Felodipine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Felodipine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Felodipine.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Felodipine.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Felodipine.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Felodipine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Felodipine can be increased when it is combined with Fusidic Acid.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Felodipine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Felodipine.Approved
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Felodipine.Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Felodipine.Experimental
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Felodipine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Felodipine.Withdrawn
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Felodipine.Approved, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Felodipine.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Felodipine.Approved
GuanazodineFelodipine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Felodipine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Felodipine.Approved, Investigational
GuanoclorFelodipine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzFelodipine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanFelodipine may increase the hypotensive activities of Guanoxan.Experimental
HachimycinThe risk or severity of adverse effects can be increased when Hachimycin is combined with Felodipine.Experimental
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Felodipine.Approved
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Felodipine.Approved
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Felodipine.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Felodipine.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Felodipine.Experimental
HexamethoniumFelodipine may increase the hypotensive activities of Hexamethonium.Experimental
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Felodipine.Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Felodipine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Felodipine.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Felodipine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Felodipine.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Felodipine.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Felodipine.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Felodipine.Approved
IdelalisibThe serum concentration of Felodipine can be increased when it is combined with Idelalisib.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Felodipine.Approved
IloprostIloprost may increase the hypotensive activities of Felodipine.Approved, Investigational
ImatinibThe metabolism of Felodipine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Felodipine.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Felodipine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Felodipine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Felodipine.Approved
IndenololFelodipine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Felodipine can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Felodipine.Approved, Investigational
IndoraminIndoramin may increase the hypotensive activities of Felodipine.Withdrawn
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Felodipine.Approved
IproclozideIproclozide may increase the hypotensive activities of Felodipine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Felodipine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Felodipine is combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Felodipine.Approved, Investigational
IsavuconazoniumThe metabolism of Felodipine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Felodipine.Approved
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Felodipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Felodipine.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Felodipine.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Felodipine.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Felodipine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Felodipine.Approved
ItraconazoleThe serum concentration of Felodipine can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Felodipine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Felodipine.Approved, Vet Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Felodipine.Approved
JosamycinThe metabolism of Felodipine can be decreased when combined with Josamycin.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Felodipine.Approved, Vet Approved
KetanserinKetanserin may increase the hypotensive activities of Felodipine.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Felodipine.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Felodipine.Approved
KetoconazoleThe serum concentration of Felodipine can be increased when it is combined with Ketoconazole.Approved, Investigational
KitasamycinThe metabolism of Felodipine can be decreased when combined with Kitasamycin.Experimental
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Felodipine.Approved
LacidipineFelodipine may increase the hypotensive activities of Lacidipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Felodipine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Felodipine.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Felodipine.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Felodipine.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Felodipine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Felodipine.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Felodipine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Felodipine.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Felodipine.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Felodipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Felodipine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Felodipine.Approved
LevodopaFelodipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Felodipine.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Felodipine.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Felodipine.Approved, Investigational
LicofeloneThe metabolism of Licofelone can be decreased when combined with Felodipine.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Felodipine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Felodipine.Approved
LinsidomineFelodipine may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Felodipine.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Felodipine.Approved
LofexidineFelodipine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Felodipine.Approved
LopinavirThe metabolism of Felodipine can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Felodipine.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Felodipine.Approved
LovastatinThe metabolism of Felodipine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Felodipine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Felodipine can be increased when combined with Lumacaftor.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Felodipine.Illicit, Withdrawn
MacitentanFelodipine may increase the hypotensive activities of Macitentan.Approved
Magnesium HydroxideThe risk or severity of adverse effects can be increased when Felodipine is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Felodipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Felodipine is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Felodipine is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineFelodipine may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Felodipine.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Felodipine.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Felodipine.Approved
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Felodipine.Approved
MelatoninMelatonin may decrease the antihypertensive activities of Felodipine.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Felodipine.Approved, Vet Approved
MepartricinThe risk or severity of adverse effects can be increased when Mepartricin is combined with Felodipine.Experimental
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Felodipine.Investigational, Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Felodipine.Experimental
MethadoneThe metabolism of Methadone can be decreased when combined with Felodipine.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Felodipine.Approved
MethohexitalMethohexital may increase the hypotensive activities of Felodipine.Approved
MethoserpidineFelodipine may increase the hypotensive activities of Methoserpidine.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Felodipine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Felodipine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Felodipine.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Felodipine.Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Felodipine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Felodipine.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Felodipine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Felodipine.Approved, Vet Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Felodipine.Approved
MetipranololThe risk or severity of adverse effects can be increased when Felodipine is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Felodipine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Felodipine.Approved, Investigational
MetyrosineFelodipine may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Felodipine.Experimental
MibefradilFelodipine may increase the hypotensive activities of Mibefradil.Withdrawn
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Felodipine.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Felodipine.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Felodipine.Approved, Illicit
MifepristoneThe serum concentration of Felodipine can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Felodipine.Approved
MinaprineMinaprine may increase the hypotensive activities of Felodipine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Felodipine.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Felodipine.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Felodipine.Investigational
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Felodipine.Approved
MitotaneThe serum concentration of Felodipine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Felodipine.Approved, Investigational
MivacuriumFelodipine may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Felodipine.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Felodipine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Felodipine.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Felodipine.Vet Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Felodipine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Felodipine.Approved
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Felodipine.Investigational
MuzolimineFelodipine may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Felodipine.Approved, Investigational
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Felodipine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Felodipine.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Felodipine is combined with Nadolol.Approved
NafcillinThe metabolism of Felodipine can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Felodipine.Approved
NaftopidilFelodipine may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Felodipine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Felodipine.Approved, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Felodipine.Approved, Vet Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Felodipine.Approved
NebivololThe risk or severity of adverse effects can be increased when Felodipine is combined with Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Felodipine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Felodipine can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Felodipine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Felodipine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Felodipine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Felodipine.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Felodipine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Felodipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Felodipine.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Felodipine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Nifedipine.Approved
NifuratelThe risk or severity of adverse effects can be increased when Nifuratel is combined with Felodipine.Experimental
NiguldipineFelodipine may increase the hypotensive activities of Niguldipine.Experimental
Nikkomycin ZThe risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Felodipine.Investigational
NilotinibThe metabolism of Felodipine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineFelodipine may increase the hypotensive activities of Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Felodipine.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Felodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Felodipine.Approved
NitrendipineFelodipine may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Felodipine.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Felodipine.Approved, Investigational
NitroprussideFelodipine may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Felodipine.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Felodipine.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Felodipine.Approved, Vet Approved
ObinutuzumabFelodipine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Felodipine.Withdrawn
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Felodipine.Investigational
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Felodipine.Approved, Investigational
OlaparibThe metabolism of Felodipine can be decreased when combined with Olaparib.Approved
OleandomycinThe metabolism of Felodipine can be decreased when combined with Oleandomycin.Vet Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Felodipine.Approved, Investigational
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Felodipine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Felodipine.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Felodipine.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Felodipine.Approved, Investigational, Vet Approved
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Felodipine.Experimental
OsimertinibThe serum concentration of Felodipine can be increased when it is combined with Osimertinib.Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Felodipine.Approved
OxprenololFelodipine may increase the hypotensive activities of Oxprenolol.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Felodipine.Approved, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Felodipine.Investigational
PalbociclibThe serum concentration of Felodipine can be increased when it is combined with Palbociclib.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Felodipine.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Felodipine is combined with Papaverine.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Felodipine.Approved
PargylinePargyline may increase the hypotensive activities of Felodipine.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Felodipine.Approved
PenbutololThe risk or severity of adverse effects can be increased when Felodipine is combined with Penbutolol.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Felodipine.Approved
PentobarbitalThe metabolism of Felodipine can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumFelodipine may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Felodipine.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Felodipine.Approved, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Felodipine.Approved
PerospironeThe metabolism of Perospirone can be decreased when combined with Felodipine.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Felodipine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Felodipine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Felodipine.Withdrawn
PhenobarbitalThe metabolism of Felodipine can be increased when combined with Phenobarbital.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Felodipine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Felodipine.Withdrawn
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Felodipine.Approved
PhentolaminePhentolamine may increase the hypotensive activities of Felodipine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Felodipine.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Felodipine.Approved
PinacidilPinacidil may increase the hypotensive activities of Felodipine.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Felodipine.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Felodipine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Felodipine.Approved
PirlindolePirlindole may increase the hypotensive activities of Felodipine.Approved
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Felodipine.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Felodipine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Felodipine.Withdrawn
PolythiazideFelodipine may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Felodipine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Felodipine.Approved
PosaconazoleThe metabolism of Felodipine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Felodipine.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Felodipine.Approved
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Felodipine.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Felodipine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Felodipine.Approved, Vet Approved
PrimidoneThe metabolism of Felodipine can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Felodipine.Approved, Vet Approved
PropofolThe metabolism of Propofol can be decreased when combined with Felodipine.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Felodipine.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Felodipine.Approved
PyrrolnitrinThe risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Felodipine.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Felodipine is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Felodipine.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Felodipine.Approved
QuinineQuinine may increase the hypotensive activities of Felodipine.Approved
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Felodipine.Experimental
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Felodipine.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Felodipine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Felodipine.Approved, Investigational
RapacuroniumFelodipine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Felodipine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Felodipine.Approved
RemikirenRemikiren may increase the hypotensive activities of Felodipine.Approved
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Felodipine.Approved, Investigational
RescinnamineFelodipine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Felodipine.Approved
RifabutinThe metabolism of Felodipine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Felodipine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Felodipine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Felodipine.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Felodipine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Felodipine is combined with Riociguat.Approved
RisperidoneFelodipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Felodipine can be decreased when combined with Ritonavir.Approved, Investigational
RituximabFelodipine may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Felodipine.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Felodipine.Investigational, Withdrawn
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Felodipine.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Felodipine.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Felodipine.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Felodipine.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Felodipine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Felodipine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Felodipine.Approved
SafrazineSafrazine may increase the hypotensive activities of Felodipine.Withdrawn
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Felodipine.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Felodipine.Approved, Vet Approved
SaprisartanFelodipine may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Felodipine can be decreased when combined with Saquinavir.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Felodipine.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Felodipine.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Felodipine.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Felodipine.Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Felodipine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Felodipine.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Felodipine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Felodipine.Approved
SiltuximabThe serum concentration of Felodipine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Felodipine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Felodipine.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Felodipine.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Felodipine.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Felodipine.Approved, Investigational
SitaxentanFelodipine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Felodipine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Felodipine.Approved
SolithromycinThe metabolism of Felodipine can be decreased when combined with Solithromycin.Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Felodipine.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Felodipine.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Felodipine.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Felodipine.Experimental
SpiraprilFelodipine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Felodipine.Approved
St. John's WortThe serum concentration of Felodipine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Felodipine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Felodipine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Felodipine.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Felodipine.Approved
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Felodipine.Approved, Vet Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Felodipine.Approved
SulfisoxazoleThe metabolism of Felodipine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TadalafilTadalafil may increase the antihypertensive activities of Felodipine.Approved, Investigational
TalinololFelodipine may increase the hypotensive activities of Talinolol.Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Felodipine.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Felodipine.Approved, Investigational
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Felodipine.Experimental
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Felodipine.Approved
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Felodipine.Approved, Investigational
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Felodipine.Approved
TelaprevirThe metabolism of Felodipine can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Felodipine can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Felodipine.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Felodipine.Approved
TemocaprilFelodipine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Felodipine.Approved
TerazosinThe risk or severity of adverse effects can be increased when Felodipine is combined with Terazosin.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Felodipine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Felodipine.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Felodipine.Experimental
TerlipressinFelodipine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Felodipine.Approved, Investigational
TetrahydropalmatineFelodipine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Felodipine.Approved, Investigational, Withdrawn
TheodrenalineFelodipine may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Felodipine.Approved
ThiamylalThiamylal may increase the hypotensive activities of Felodipine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Felodipine.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Felodipine.Withdrawn
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Felodipine.Approved
TiboloneFelodipine may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Felodipine.Approved
TiclopidineThe metabolism of Felodipine can be decreased when combined with Ticlopidine.Approved
TicrynafenFelodipine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Felodipine.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Felodipine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Felodipine.Approved
TocilizumabThe serum concentration of Felodipine can be decreased when it is combined with Tocilizumab.Approved
TolazolineTolazoline may increase the hypotensive activities of Felodipine.Approved, Vet Approved
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Felodipine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Felodipine.Approved, Withdrawn
TolciclateThe risk or severity of adverse effects can be increased when Tolciclate is combined with Felodipine.Experimental
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Felodipine.Approved, Vet Approved
TolonidineFelodipine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Felodipine.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Felodipine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Felodipine.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Felodipine.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Felodipine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Felodipine.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Felodipine.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Felodipine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Felodipine.Approved
TravoprostTravoprost may increase the hypotensive activities of Felodipine.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Felodipine.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Felodipine.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Felodipine.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Felodipine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Felodipine.Experimental
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Felodipine.Approved
TrimethaphanTrimethaphan may increase the hypotensive activities of Felodipine.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Felodipine.Approved, Vet Approved
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Felodipine.Approved, Investigational
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Felodipine.Withdrawn
TylosinThe metabolism of Felodipine can be decreased when combined with Tylosin.Vet Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Felodipine.Experimental
UdenafilUdenafil may increase the antihypertensive activities of Felodipine.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Felodipine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Felodipine.Approved
UnoprostoneFelodipine may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Felodipine.Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Felodipine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Felodipine.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Felodipine.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Felodipine.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Felodipine.Approved
VenlafaxineThe metabolism of Felodipine can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Felodipine.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Felodipine.Approved
VincamineFelodipine may increase the hypotensive activities of Vincamine.Experimental
VincristineThe serum concentration of Vincristine can be increased when it is combined with Felodipine.Approved, Investigational
VinpocetineFelodipine may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Felodipine.Approved
VoriconazoleThe metabolism of Felodipine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Felodipine.Approved
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Felodipine.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Felodipine.Approved
XipamideFelodipine may increase the hypotensive activities of Xipamide.Experimental
XylometazolineFelodipine may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Felodipine.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Felodipine.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Felodipine.Approved
ZiprasidoneThe metabolism of Felodipine can be decreased when combined with Ziprasidone.Approved
ZofenoprilFelodipine may increase the hypotensive activities of Zofenopril.Experimental
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Felodipine.Approved
Food Interactions
  • Grapefruit down regulates post-translational expression of CYP3A4, the major metabolizing enzyme of nifedipine. Grapefruit, in all forms (e.g. whole fruit, juice and rind), can significantly increase serum levels of nifedipine and may cause toxicity. Avoid grapefruit products while on this medication.
  • Take without regard to meals.

References

Synthesis Reference

Vinay Sharma, "Preparation of micron-size felodipine particles by microfluidization." U.S. Patent US20020086061, issued July 04, 2002.

US20020086061
General References
  1. Dunselman PH, Edgar B: Felodipine clinical pharmacokinetics. Clin Pharmacokinet. 1991 Dec;21(6):418-30. [PubMed:1782737]
External Links
Human Metabolome Database
HMDB15158
KEGG Drug
D00319
PubChem Compound
3333
PubChem Substance
46506968
ChemSpider
3216
BindingDB
189379
ChEBI
585948
ChEMBL
CHEMBL1480
Therapeutic Targets Database
DAP000487
PharmGKB
PA449591
IUPHAR
4190
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Felodipine
ATC Codes
C08CA02 — FelodipineC09BB05 — Ramipril and felodipine
AHFS Codes
  • 24:28.08 — Dihydropyridines
FDA label
Download (228 KB)
MSDS
Download (55.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedTreatmentFood-Drug Interactions1
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Hypercholesterolaemia / Hypertensive / Type 2 Diabetes Mellitus1
3CompletedTreatmentBMI >30 kg/m2 / Hypertensive1
4CompletedPreventionDisorders Related to Lung Transplantation1
4CompletedTreatmentHypertensive2
4CompletedTreatmentHypertensive / Left Ventricular Hypertrophy1
4Unknown StatusTreatmentHypertensive / Sexual Dysfunctions1
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedNot AvailableHypertensive1
Not AvailableCompletedTreatmentHypertensive1
Not AvailableUnknown StatusBasic ScienceHypertensive / Insulin Resistance / Microcirculation1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral
Tablet, film coatedOral2.5 mg/1
Tablet, film coated, extended releaseOral10 mg/1
Tablet, film coated, extended releaseOral2.5 mg/1
Tablet, film coated, extended releaseOral5 mg/1
Tablet, extended releaseOral10 mg/1
Tablet, extended releaseOral2.5 mg/1
Tablet, extended releaseOral5 mg/1
Tablet, extended releaseOral10 mg
Tablet, extended releaseOral2.5 mg
Tablet, extended releaseOral5 mg
Prices
Unit descriptionCostUnit
Plendil 10 mg 24 Hour tablet3.17USD tablet
Plendil er 10 mg tablet3.05USD tablet
Plendil 10 mg tablet sa2.96USD tablet
Felodipine 10 mg 24 Hour tablet2.95USD tablet
Plendil er 2.5 mg tablet2.94USD tablet
Felodipine er 10 mg tablet2.72USD tablet
Plendil er 5 mg tablet2.6USD tablet
Plendil 5 mg 24 Hour tablet1.77USD tablet
Plendil 2.5 mg 24 Hour tablet1.76USD tablet
Felodipine 5 mg 24 Hour tablet1.67USD tablet
Plendil 2.5 mg tablet sa1.65USD tablet
Plendil 5 mg tablet sa1.65USD tablet
Felodipine 2.5 mg 24 Hour tablet1.57USD tablet
Felodipine er 2.5 mg tablet1.51USD tablet
Felodipine er 5 mg tablet1.51USD tablet
Renedil 10 mg Extended-Release Tablet1.22USD tablet
Plendil 10 mg Extended-Release Tablet1.15USD tablet
Renedil 5 mg Extended-Release Tablet0.81USD tablet
Plendil 5 mg Extended-Release Tablet0.77USD tablet
Sandoz Felodipine 10 mg Extended-Release Tablet0.73USD tablet
Renedil 2.5 mg Extended-Release Tablet0.6USD tablet
Plendil 2.5 mg Extended-Release Tablet0.57USD tablet
Sandoz Felodipine 5 mg Extended-Release Tablet0.48USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)145 °CNot Available
water solubility19.7 mg/LNot Available
logP3.86SANGSTER (1994)
Caco2 permeability-4.64ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00715 mg/mLALOGPS
logP4.36ALOGPS
logP3.44ChemAxon
logS-4.7ALOGPS
pKa (Strongest Basic)5.39ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area64.63 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity99.2 m3·mol-1ChemAxon
Polarizability38.04 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9878
Blood Brain Barrier-0.83
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.5149
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.8664
CYP450 2C9 substrateNon-substrate0.8357
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6954
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9304
Ames testNon AMES toxic0.7849
CarcinogenicityNon-carcinogens0.7511
BiodegradationNot ready biodegradable0.9527
Rat acute toxicity2.4526 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9455
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udu-0139000000-085071c20c5d0c134d8f

Taxonomy

Description
This compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Hydropyridines
Direct Parent
Dihydropyridinecarboxylic acids and derivatives
Alternative Parents
Dichlorobenzenes / Dicarboxylic acids and derivatives / Aryl chlorides / Vinylogous amides / Methyl esters / Enoate esters / Amino acids and derivatives / Enamines / Dialkylamines / Azacyclic compounds
show 5 more
Substituents
Dihydropyridinecarboxylic acid derivative / 1,2-dichlorobenzene / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Dicarboxylic acid or derivatives / Benzenoid / Vinylogous amide
show 22 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
ethyl ester, dichlorobenzene, methyl ester, dihydropyridine (CHEBI:585948)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1C
Uniprot ID
Q13936
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1C
Molecular Weight
248974.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T: Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1999 Nov;291(2):464-73. [PubMed:10525060]
  3. Zahradnikova A, Minarovic I, Zahradnik I: Competitive and cooperative effects of Bay K8644 on the L-type calcium channel current inhibition by calcium channel antagonists. J Pharmacol Exp Ther. 2007 Aug;322(2):638-45. Epub 2007 May 2. [PubMed:17475903]
  4. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-...
Gene Name
CACNA2D1
Uniprot ID
P54289
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-1
Molecular Weight
124566.93 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T: Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1999 Nov;291(2):464-73. [PubMed:10525060]
  3. Zahradnikova A, Minarovic I, Zahradnik I: Competitive and cooperative effects of Bay K8644 on the L-type calcium channel current inhibition by calcium channel antagonists. J Pharmacol Exp Ther. 2007 Aug;322(2):638-45. Epub 2007 May 2. [PubMed:17475903]
  4. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB2
Uniprot ID
Q08289
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-2
Molecular Weight
73579.925 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T: Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1999 Nov;291(2):464-73. [PubMed:10525060]
  3. Zahradnikova A, Minarovic I, Zahradnik I: Competitive and cooperative effects of Bay K8644 on the L-type calcium channel current inhibition by calcium channel antagonists. J Pharmacol Exp Ther. 2007 Aug;322(2):638-45. Epub 2007 May 2. [PubMed:17475903]
  4. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1D
Uniprot ID
Q01668
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1D
Molecular Weight
245138.75 Da
References
  1. Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1S
Uniprot ID
Q13698
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1S
Molecular Weight
212348.1 Da
References
  1. Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1H
Uniprot ID
O95180
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1H
Molecular Weight
259160.2 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221]
  2. Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-t...
Gene Name
CACNA2D2
Uniprot ID
Q9NY47
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-2
Molecular Weight
129816.095 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221]
  2. Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Titin binding
Specific Function
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number...
Gene Name
CALM1
Uniprot ID
P0DP23
Uniprot Name
Calmodulin
Molecular Weight
16837.47 Da
References
  1. Bostrom SL, Westerlund C, Rochester S, Vogel HJ: Binding of a dihydropyridine felodipine-analogue to calmodulin and related calcium-binding proteins. Biochem Pharmacol. 1988 Oct 1;37(19):3723-8. [PubMed:3178884]
  2. Johnson JD, Andrews CT, Khabbaza EJ, Mills JS: The interaction of felodipine with calcium-binding proteins. J Cardiovasc Pharmacol. 1987;10 Suppl 1:S53-9. [PubMed:2442519]
  3. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041]
  4. Lamers JM, Verdouw PD, Mas-Oliva J: The effects of felodipine and bepridil on calcium-stimulated calmodulin binding and calcium pumping ATPase of cardiac sarcolemma before and after removal of endogenous calmodulin. Mol Cell Biochem. 1987 Dec;78(2):169-76. [PubMed:2964559]
  5. Mills JS, Bailey BL, Johnson JD: Cooperativity among calmodulin's drug binding sites. Biochemistry. 1985 Aug 27;24(18):4897-902. [PubMed:4074665]
  6. Walsh MP, Sutherland C, Scott-Woo GC: Effects of felodipine (a dihydropyridine calcium channel blocker) and analogues on calmodulin-dependent enzymes. Biochem Pharmacol. 1988 Apr 15;37(8):1569-80. [PubMed:2833901]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a preference for cGMP as...
Gene Name
PDE1B
Uniprot ID
Q01064
Uniprot Name
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B
Molecular Weight
61379.235 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041]
  2. Sharma RK, Wang JH, Wu Z: Mechanisms of inhibition of calmodulin-stimulated cyclic nucleotide phosphodiesterase by dihydropyridine calcium antagonists. J Neurochem. 1997 Aug;69(2):845-50. [PubMed:9231746]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a higher affinity for cG...
Gene Name
PDE1A
Uniprot ID
P54750
Uniprot Name
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A
Molecular Weight
61251.38 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041]
  2. Sharma RK, Wang JH, Wu Z: Mechanisms of inhibition of calmodulin-stimulated cyclic nucleotide phosphodiesterase by dihydropyridine calcium antagonists. J Neurochem. 1997 Aug;69(2):845-50. [PubMed:9231746]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Zinc ion binding
Specific Function
Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates targ...
Gene Name
NR3C2
Uniprot ID
P08235
Uniprot Name
Mineralocorticoid receptor
Molecular Weight
107066.575 Da
References
  1. Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR, Funder JW, Hu X: A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension. 2008 Mar;51(3):742-8. doi: 10.1161/HYPERTENSIONAHA.107.103580. Epub 2008 Feb 4. [PubMed:18250364]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Calcium ion binding
Specific Function
Troponin is the central regulatory protein of striated muscle contraction. Tn consists of three components: Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site fo...
Gene Name
TNNC2
Uniprot ID
P02585
Uniprot Name
Troponin C, skeletal muscle
Molecular Weight
18121.895 Da
References
  1. Bostrom SL, Westerlund C, Rochester S, Vogel HJ: Binding of a dihydropyridine felodipine-analogue to calmodulin and related calcium-binding proteins. Biochem Pharmacol. 1988 Oct 1;37(19):3723-8. [PubMed:3178884]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Troponin t binding
Specific Function
Troponin is the central regulatory protein of striated muscle contraction. Tn consists of three components: Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site fo...
Gene Name
TNNC1
Uniprot ID
P63316
Uniprot Name
Troponin C, slow skeletal and cardiac muscles
Molecular Weight
18402.36 Da
References
  1. Bostrom SL, Westerlund C, Rochester S, Vogel HJ: Binding of a dihydropyridine felodipine-analogue to calmodulin and related calcium-binding proteins. Biochem Pharmacol. 1988 Oct 1;37(19):3723-8. [PubMed:3178884]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Galetin A, Clarke SE, Houston JB: Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos. 2002 Dec;30(12):1512-22. [PubMed:12433827]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Schoch GA, Yano JK, Sansen S, Dansette PM, Stout CD, Johnson EF: Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem. 2008 Jun 20;283(25):17227-37. doi: 10.1074/jbc.M802180200. Epub 2008 Apr 15. [PubMed:18413310]
  2. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514]

Drug created on June 13, 2005 07:24 / Updated on October 23, 2017 14:13